Central fatness and risk of all cause mortality: systematic review and dose-response meta-analysis of 72 prospective cohort studies
Jayedi A, Soltani S, Zargar MS, et al.
BMJ. 2020;370:m3324
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Dapagliflozin in patients with chronic kidney disease
Heerspink HJL, Stefànsson BV, Correa-Rotter R, et al.
N Engl J Med. Pub. online 24 September 2020
Leggi
Determinants of good metabolic control without weight gain in type 2 diabetes management: a machine learning analysis
Giorda CB, Pisani F, De Micheli A, Ponzani P, Russo G, Guaita G, Zilich R, Musacchio N; Associazione Medici Diabetologi (AMD) Annals Study Group
BMJ Open Diabetes Res Care. 2020;8(1):e001362
Leggi
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials
Groop P-H, Dandona P, Phillip M, et al.
The Lancet Diabetes & Endocrinology. 2020;8(10):845-54
Leggi
Diabetes in ageing: pathways for developing the evidence base for clinical guidance
Munshi MN, Meneilly GS, Rodríguez-Mañas L, et al.
The Lancet Diabetes & Endocrinology. 2020;8(10):855-86
Leggi
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
Feig DS, Donovan LE, Zinman B, et al.
The Lancet Diabetes & Endocrinology. 2020;8(10):834-44
Leggi
Visit-to-visit hemoglobin A1c variability is associated with the risk of lower-extremity amputation in patients with type 2 diabetes
Fan Y, Shen Y, Zhou J, et al.
Diabetes Care. 2020 dc201615
Leggi
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes
Cravalho CKL, Meyers AG, Mabundo LS, et al.
Diabetologia. 2020,63,2194-204
Leggi
Organisation of the human pancreas in health and in diabetes
Atkinson MA, Campbell-Thompson M, Kusmartseva I, Kaestner KH
Diabetologia. 2020,63,1966-73
Leggi
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Canna F, Ferreira JP, Pocock SJ, et al.
Lancet. 2020;S0140-6736(20)31824-9
Leggi